Telomeres, stem cells, senescence, and cancer

Journal of Clinical Investigation

Volumn 113, Issue 2, 2004, Pages 160-168

  Sharpless, Norman E ^a,c   DePinho, Ronald A ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TELOMERASE;

AGING; APOPTOSIS; CANCER INHIBITION; CARCINOGENESIS; GENE MUTATION; HOMEOSTASIS; HUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL; TELOMERE; ANIMAL; BIOLOGICAL MODEL; CELL AGING; METABOLISM; MUTATION; NEOPLASM; PATHOLOGY; TUMOR SUPPRESSOR GENE; ULTRASTRUCTURE;

AGING; ANIMALS; APOPTOSIS; CELL AGING; GENES, TUMOR SUPPRESSOR; HUMANS; MODELS, BIOLOGICAL; MODELS, GENETIC; MUTATION; NEOPLASMS; STEM CELLS; TELOMERASE; TELOMERE;

EID: 85047689866     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI20761     Document Type: Review

References (123)

1. Guarente, L., and Kenyon, C. 2000. Genetic pathways that regulate ageing in model organisms. Nature. 408:255-262.
2. Gems, D., and Partridge, L. 2001. Insulin/IGF signalling and ageing: seeing the bigger picture. Curr. Opin. Genet. Dev. 11:287-292.
3. Mori, H., et al. 2002. Chromosome translocations and covert leukemic clones are generated during normal fetal development. Proc. Natl. Natl. Acad. Sci. U. S. A. 99:8242-8247.
4. Liu, Y., Hernandez, A.M., Shibata, D., and Cortopassi, G.A. 1994. BCL2 translocation frequency rises with age in humans. Proc. Natl. Acad. Sci. U. S. A. 91:8910-8914.
5. Wright, W.E., and Shay, J.W. 2002. Historical claims and current interpretations of replicative aging. Nat. Biotechnol. 20:682-688.
6. Campisi, J. 2001. Cellular senescence as a tumor-suppressor mechanism. Trends Cell Biol. 11:S27-S31.
7. Kamijo, T., et al. 1997. Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell. 91:649-659.
8. Stein, G.H., Drullinger, L.F., Soulard, A., and Dulic, V. 1999. Differential roles for cyclin-dependent kinase inhibitors p21 and p16 in the mechanisms of senescence and differentiation in human fibroblasts. Mol. Cell. Biol. 19:2109-2117.
9. Alcorta, D.A., et al. 1996. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 93:13742-13747.
10. Sage, J., Miller, A.L., Perez-Mancera, P.A., Wysocki, J.M., and Jacks, T. 2003. Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature. 424:223-228.
11. Classon, M., and Harlow, E. 2002. The retinoblastoma tumour suppressor in development and cancer. Nat. Rev. Cancer. 2:910-917.
12. Vousden, K.H. 2000. p53: death star. Cell. 103:691-694.
13. Sharpless, N.E., and DePinho, R.A. 2002. p53: good cop/bad cop. Cell. 110:9-12.
14. Levine, A.J. 1997. p53, the cellular gatekeeper for growth and division. Cell. 88:323-331.
15. Pomerantz, J., et al. 1998. The Ink4a tumor suppressor gene product, p19Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell. 92:713-723.
16. Zindy, F., et al. 1998. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 12:2424-2433.
17. de Stanchina, E., et al. 1998. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes Dev. 12:2434-2442.
18. Zhang, Y., Xiong, Y., and Yarbrough, W.G. 1998. ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell. 92:725-734.
19. Stott, F.J., et al. 1998. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J. 17:5001-5014.
20. Kamijo, T., et al. 1998. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. Proc. Natl. Acad. Sci. U. S. A. 95:8292-8297.
21. Zhu, J., Woods, D., McMahon, M., and Bishop, J.M. 1998. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev. 12:2997-3007.
22. Serrano, M., Lin, A.W., McCurrach, M.E., Beach, D., and Lowe, S.W. 1997. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell. 88:593-602.
23. Lin, A.W., et al. 1998. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 12:3008-3019.
24. Zindy, F., Quelle, D.E., Roussel, M.F., and Sherr, C.J. 1997. Expression of the p16INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene. 15:203-211.
25. Beausejour, C.M., et al. 2003. Reversal of human cellular senescence: Roles of the p53 and p16 pathways. EMBO J. 22:4212-4222.
26. Dirac, A.M., and Bernards, R. 2003. Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. J. Biol. Chem. 278:11731-11734.
27. Gire, V., and Wynford-Thomas, D. 1998. Reinitiation of DNA synthesis and cell division in senescent human fibroblasts by microinjection of anti-p53 antibodies. Mol. Cell. Biol. 18:1611-1621.
28. Sharpless, N.E. 2003. The persistence of senescence. Sci. Aging Knowledge Environ. 2003:PE24.
29. Narita, M., et al. 2003. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell. 113:703-716.
30. Wong, K.K., et al. 2003. Telomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing. Nature. 421:643-648.
31. Rudolph, K.L., et al. 1999. Longevity, stress response, and cancer in aging telomerase-deficient mice. Cell. 96:701-712.
32. Lee, H.W., et al. 1998. Essential role of mouse telomerase in highly proliferative organs. Nature. 392:569-574.
33. Lowe, S.W., Ruley, H.E., Jacks, T., and Housman, D.E. 1993. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 74:957-967.
34. Yonish-Rouach, E., et al. 1991. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 352:345-347.
35. Schmitt, C.A., et al. 2002. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell. 1:289-298.
36. Lu, X., et al. 2001. Selective inactivation of p53 facilitates mouse epithelial tumor progression without chromosomal instability. Mol. Cell. Biol. 21:6017-6030.
37. Chin, L., et al. 1999. p53 deficiency rescues the adverse effects of telomere loss and cooperates with telomere dysfunction to accelerate carcinogenesis. Cell. 97:527-538.
38. Artandi, S.E., et al. 2000. Telomere dysfunction promotes non-reciprocal translocations and epithelial cancers in mice. Nature. 406:641-645.
39. Ausserlechner, M.J., et al. 2001. The cell cycle inhibitor p16(INK4A) sensitizes lymphoblastic leukemia cells to apoptosis by physiologic glucocorticoid levels. J. Biol. Chem. 276:10984-10989.
40. Lagresle, C., et al. 2002. Transgenic expression of the p16(INK4a) cyclin-dependent kinase inhibitor leads to enhanced apoptosis and differentiation arrest of CD4-CD8-immature thymocytes. J. Immunol. 168:2325-2331.
41. Plath, T., et al. 2000. A novel function for the tumor suppressor p16(INK4a): induction of anoikis via upregulation of the alpha(5)beta(1) fibronectin receptor. J. Cell Biol. 150:1467-1478.
42. Tamm, I., et al. 2002. Adenovirus-mediated gene transfer of P16INK4/ CDKN2 into bax-negative colon cancer cells induces apoptosis and tumor regression in vivo. Cancer Gene Ther. 9:641-650.
43. Maser, R.S., and DePinho, R.A. 2002. Connecting chromosomes, crisis, and cancer. Science. 297:565-569.
44. de Lange, T. 2002. Protection of mammalian telomeres. Oncogene. 21:532-540.
45. van Steensel, B., Smogorzewska, A., and de Lange, T. 1998. TRF2 protects human telomeres from end-to-end fusions. Cell. 92:401-413.
46. Stewart, S.A., et al. 2003. Erosion of the telomeric single-strand overhang at replicative senescence. Nat. Genet. 33:492-496.
47. Masutomi, K., et al. 2003. Telomerase maintains telomere structure in normal human cells. Cell. 114:241-253.
48. Broccoli, D., Young, J.W., and de Lange, T. 1995. Telomerase activity in normal and malignant hematopoietic cells. Proc. Natl. Acad. Sci. U. S. A. 92:9082-9086.
49. Counter, C.M., Gupta, J., Harley, C.B., Leber, B., and Bacchetti, S. 1995. Telomerase activity in normal leukocytes and in hematologic malignancies. Blood. 85:2315-2320.
50. Wright, W.E., Piatyszek, M.A., Rainey, W.E., Byrd, W., and Shay, J.W. 1996. Telomerase activity in human germline and embryonic tissues and cells. Dev. Genet. 18:173-179.
51. Weng, N.P., Levine, B.L., June, C.H., and Hodes, R.J. 1996. Regulated expression of telomerase activity in human T lymphocyte development and activation. J. Exp. Med. 183:2471-2479.
52. Bodnar, A.G., et al. 1998. Extension of life-span by introduction of telomerase into normal human cells. Science. 279:349-352.
53. Smogorzewska, A., and de Lange, T. 2002. Different telomere damage signaling pathways in human and mouse cells. EMBO J. 21:4338-4348.
54. Greenberg, RA., et al. 1999. Short dysfunctional telomeres impair tumorigenesis in the INK4a(delta2/3) cancer-prone mouse. Cell. 97:515-525.
55. Foster, S.A., Wong, D.J., Barrett, M.T., and Galloway, D.A. 1998. Inactivation of p16 in human mammary epithelial cells by CpG island methylation. Mol. Cell. Biol. 18:1793-1801.
56. Huschtscha, L.I., et al. 1998. Loss of p16INK4 expression by methylation is associated with lifespan extension of human mammary epithelial cells. Cancer Res. 58:3508-3512.
57. Kiyono, T., et al. 1998. Both Rb/p16INK4a inactivation and telomerase activity are required to immortalize human epithelial cells. Nature. 396:84-88.
58. Nielsen, G.P., et al. 1999. Immunohistochemical survey of p16INK4A expression in normal human adult and infant tissues. Lab. Invest. 79:1137-1143.
59. Counter, C.M., et al. 1992. Telomere shortening associated with chromosome instability is arrested in immortal cells which express telomerase activity. EMBO J. 11:1921-1929.
60. Coursen, J.D., Bennett, W.P., Gollahon, L., Shay, J.W., and Harris, C.C. 1997. Genomic instability and telomerase activity in human bronchial epithelial cells during immortalization by human papillomavirus-16 E6 and E7 genes. Exp. Cell Res. 235:245-253.
61. Counter, C.M., Botelho, F.M., Wang, P., Harley, C.B., and Bacchetti, S. 1994. Stabilization of short telomeres and telomerase activity accompany immortalization of Epstein-Barr virus-transformed human B lymphocytes. J. Virol. 68:3410-3414.
62. Bryan, T.M., Englezou, A., Gupta, J., Bacchetti, S., and Reddel, R.R. 1995. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J. 14:4240-4248.
63. Bryan, T.M., Marusic, L., Bacchetti, S., Namba, M., and Reddel, R.R. 1997. The telomere lengthening mechanism in telomerase-negative immortal human cells does not involve the telomerase RNA subunit. Hum. Mol. Genet. 6:921-926.
64. Hiyama, K., et al. 1995. Telomerase activity in small-cell and non-small-cell lung cancers. J. Natl. Cancer Inst. 87:895-902.
65. Kim, N.W., et al. 1994. Specific association of human telomerase activity with immortal cells and cancer. Science. 266:2011-2015.
66. Hiyama, E., et al. 1995. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat. Med. 1:249-255.
67. Hahn, W.C., et al. 1999. Creation of human tumour cells with defined genetic elements. Nature. 400:464-468.
68. Gonzalez-Suarez, E., Samper, E., Flores, J.M., and Blasco, M.A. 2000. Telomerase-deficient mice with short telomeres are resistant to skin tumorigenesis. Nat. Genet. 26:114-117.
69. Rudolph, K.L., Millard, M., Bosenberg, M.W., and DePinho, R.A. 2001. Telomere dysfunction and evolution of intestinal carcinoma in mice and humans. Nat. Genet. 28:155-159.
70. Shay, J.W., and Wright, W.E. 2002. Telomerase: a target for cancer therapeutics. Cancer Cell. 2:257-265.
71. Strampfer, M.R., et al. 2001. Expression of the telomerase catalytic subunit, hTERT, induces resistance to transforming growth factor beta growth inhibition in p16INK4A(-) human mammary epithelial cells. Proc. Natl. Acad. Sci. U. S. A. 98:4498-4503.
72. Artandi, S.E., et al. 2002. Constitutive telomerase expression promotes mammary carcinomas in aging mice. Proc. Natl. Acad. Sci. U. S. A. 99:8191-8196.
73. Gonzalez-Suarez, E., et al. 2001. Increased epidermal tumors and increased skin wound healing in transgenic mice overexpressing the catalytic subunit of telomerase, mTERT, in basal keratinocytes. EMBO J. 20:2619-2630.
74. Chang, S., Khoo, C.M., Naylor, M.L., Maser, R.S., and DePinho, R.A. 2003. Telomere-based crisis: functional differences between telomerase activation and ALT in tumor progression. Genes Dev. 17:88-100.
75. Metcalfe, J.A., et al. 1996. Accelerated telomere shortening in ataxia telangiectasia. Nat. Genet. 13:350-353.
76. Xia, S.J., Shammas, M.A., and Shmookler Reis, R.J. 1996. Reduced telomere length in ataxia-telangiectasia fibroblasts. Mutat. Res. 364:1-11.
77. Borghesani, P.R., et al. 2000. Abnormal development of Purkinje cells and lymphocytes in Atm mutant mice. Proc. Natl. Acad. Sci. U. S. A. 97:3336-3341.
78. Barlow, C., et al. 1996. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell. 86:159-171.
79. Xu, Y., et al. 1996. Targeted disruption of ATM leads to growth retardation, chromosomal fragmentation during meiosis, immune defects, and thymic lymphoma. Genes Dev. 10:2411-2422.
80. Elson, A., et al. 1996. Pleiotropic defects in ataxia-telangiectasia protein-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 93:13084-13089.
81. Liao, M.J., and Van Dyke, T. 1999. Critical role for Atm in suppressing V(D)J recombination-driven thymic lymphoma. Genes Dev. 13:1246-1250.
82. Vulliamy, T., et al. 2001. The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita. Nature. 413:432-435.
83. Kitada, T., Seki, S., Kawakita, N., Kuroki, T., and Monna, T. 1995. Telomere shortening in chronic liver diseases. Biochem. Biophys. Res. Commun. 211:33-39.
84. Miura, N., et al. 1997. Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis. Cancer Genet. Cytogenet. 93:56-62.
85. Urabe, Y., et al. 1996. Telomere length in human liver diseases. Liver. 16:293-297.
86. Wiemann, S.U., et al. 2002. Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J. 16:935-942.
87. Samani, N.J., Boultby, R., Butler, R., Thompson, J.R., and Goodall, A.H. 2001. Telomere shortening in atherosclerosis. Lancet. 358:472-473.
88. Obana, N., et al. 2003. Telomere shortening of peripheral blood mononuclear cells in coronary disease patients with metabolic disorders. Intern. Med. 42:150-153.
89. Cawthon, R.M., Smith, K.R., O'Brien, E., Sivatchenko, A., and Kerber, R.A. 2003. Association between telomere length in blood and mortality in people aged 60 years or older. Lancet. 361:393-395.
90. Artandi, S.E., and DePinho, R.A. 2000. A critical role for telomeres in suppressing and facilitating carcinogenesis. Curr. Opin. Genet. Dev. 10:39-46.
91. O'Hagan, R.C., et al. 2002. Telomere dysfunction provokes regional amplification and deletion in cancer genomes. Cancer Cell. 2:149-155.
92. Buerger, H., et al. 1999. Comparative genomic hybridization of ductal carcinoma in situ of the breast-evidence of multiple genetic pathways. J. Pathol. 187:396-402.
93. Waldman, F.M., et al. 2000. Chromosomal alterations in ductal carcinomas in situ and their in situ recurrences. J. Natl. Cancer Inst. 92:313-320.
94. Moore, E., Magee, H., Coyne, J., Gorey, T., and Dervan, P.A. 1999. Wide-spread chromosomal abnormalities in high-grade ductal carcinoma in situ of the breast. Comparative genomic hybridization study of pure high-grade DCIS. J. Pathol. 187:403-409.
95. Walch, A.K., et al. 2000. Chromosomal imbalances in Barrett's adenocarcinoma and the metaplasia-dysplasia-carcinoma sequence. Am. J. Pathol. 156:555-566.
96. van Dekken, H., Vissers, C.J., Tilanus, H.W., Tanke, H.J., and Rosenberg, C. 1999. Clonal analysis of a case of multifocal oesophageal (Barrett's) adenocarcinoma by comparative genomic hybridization. J. Pathol. 188:263-266.
97. Lord, R.V., et al. 2000. Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence. J. Gastrointest. Surg. 4:135-142.
98. Chadeneau, C., Hay, K., Hirte, H.W., Gallinger, S., and Bacchetti, S. 1995. Telomerase activity associated with acquisition of malignancy in human colorectal cancer. Cancer Res. 55:2533-2536.
99. Engelhardt, M., Drullinsky, P., Guillem, J., and Moore, M.A. 1997. Telomerase and telomere length in the development and progression of pre-malignant lesions to colorectal cancer. Clin. Cancer Res. 3:1931-1941.
100. Yan, P., Saraga, E.P., Bouzourene, H., Bosman, F.T., and Benhattar, J. 1999. Telomerase activation in colorectal carcinogenesis. J. Pathol. 189:207-212.
101. Tang, R., Cheng, A.J., Wang, J.Y., and Wang, T.C. 1998. Close correlation between telomerase expression and adenomatous polyp progression in multistep colorectal carcinogenesis. Cancer Res. 58:4052-4054.
102. Poremba, C., et al. 1998. Telomerase activity in human proliferative breast lesions. Int. J. Oncol. 12:641-648.
103. Tsao, J., et al. 1997. Telomerase activity in normal and neoplastic breast. Clin. Cancer Res. 3:627-631.
104. Wu, X., et al. 2003. Telomere dysfunction: a potential cancer predisposition factor. J. Natl. Cancer Inst. 95:1211-1218.
105. Wong, K.K., and DePinho, R.A. 2003. Walking the telomere plank into cancer. J. Natl. Cancer Inst. 95:1184-1186.
106. Greenberg, R.A., et al. 1999. Telomerase reverse transcriptase gene is a direct target of c-Myc but is not functionally equivalent in cellular transformation. Oncogene. 18:1219-1226.
107. Wang, J., Xie, L.Y., Allan, S., Beach, D., and Hannon, G.J. 1998. Myc activates telomerase. Genes Dev. 12:1769-1774.
108. Donehower, L.A., et al. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous rumours. Nature. 356:215-221.
109. Sharpless, N.E., et al. 2001. Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature. 413:86-91.
110. Krimpenfort, P., Quon, K.C., Mooi, W.J., Loonstra, A., and Berns, A. 2001. Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature. 413:83-86.
111. Blasco, M.A., et al. 1997. Telomere shortening and tumor formation by mouse cells lacking telomerase RNA. Cell. 91:25-34.
112. Tyner, S.D., et al. 2002. p53 mutant mice that display early ageing-associated phenotypes. Nature. 415:45-53.
113. Garcia-Cao, I., et al. 2002. "Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally. EMBO J. 21:6225-6235.
114. Engwerda, C.R., Handwerger, B.S., and Fox, B.S. 1994. Aged T cells are hyporesponsive to costimulation mediated by CD28. J. Immunol. 152:3740-3747.
115. Hastie, N.D., et al. 1990. Telomere reduction in human colorectal carcinoma and with ageing. Nature. 346:866-868.
116. Allsopp, R.C., et al. 1992. Telomere length predicts replicative capacity of human fibroblasts. Proc. Natl. Acad. Sci. U. S. A. 89:10114-10118.
117. Frenck, R.W., Jr., Blackburn, E.H., and Shannon, K.M. 1998. The rate of telomere sequence loss in human leukocytes varies with age. Proc. Natl. Acad. Sci. U. S. A. 95:5607-5610.
118. Hemann, M.T., Strong, M.A., Hao, L.Y., and Greider, C.W. 2001. The shortest telomere, not average telomere length, is critical for cell viability and chromosome stability. Cell. 107:67-77.
119. Park, LK., et al. 2003. Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature. 423:302-305.
120. Lewis, J.L., et al. 2001. The influence of INK4 proteins on growth and self-renewal kinetics of hematopoietic progenitor cells. Blood. 97:2604-2610.
121. Spillman, B.C., and Lubitz, J. 2000. The effect of longevity on spending for acute and long-term care. N. Engl. J. Med. 342:1409-1415.
122. Lubitz, J., Cai, L., Kramarow, E., and Lentzner, H. 2003. Health, life expectancy, and health care spending among the elderly. N. Engl. J. Med. 349:1048-1055.
123. Cutler, D.M. 2003. Disability and the future of Medicare. N. Engl. J. Med. 349:1084-1085.